

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)**

Interim Condensed Consolidated Financial Statements  
For the three months period ended 31 March 2025

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Interim condensed consolidated financial statements  
For the three months period ended 31 March 2025**

---

<b>INDEX</b>	<b>PAGE</b>
Independent auditor's review report	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of income	3
Interim condensed consolidated statement of comprehensive income	4
Interim condensed consolidated statement of changes in equity	5
Interim condensed consolidated statement of cash flows	6
Notes to the interim condensed consolidated financial statements	7 – 13



**Ernst & Young Professional Services (Professional LLC)**  
**Paid-up capital (SR 5,500,000 – Five million five hundred thousand Saudi Riyal)**  
Head Office  
Al Faisaliah Office Tower, 14<sup>th</sup> Floor  
King Fahad Road  
P.O. Box 2732  
Riyadh 11461  
Kingdom of Saudi Arabia

C.R. No. 1010383821

Tel: +966 11 215 9898

+966 11 273 4740

Fax: +966 11 273 4730

ey.ksa@sa.ey.com

ey.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED  
FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF  
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY  
(SAUDI JOINT STOCK COMPANY)**

**Introduction:**

We have reviewed the accompanying interim condensed consolidated statement of financial position of Dr. Sulaiman Al Habib Medical Services Group Company ("the Company") and its subsidiaries (collectively with the Company referred to as "the Group") as at 31 March 2025, and the related interim condensed consolidated statements of income and comprehensive income for the three-month period ended 31 March 2025, and the related interim condensed consolidated statements of changes in equity and cash flows for the three-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

**Scope of Review:**

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion:**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services

Fahad M. Al-Toaimi  
Certified Public Accountant  
License No. (354)



Riyadh: 6 Dhu Al-Qadah 1446H  
(4 May 2025)

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Interim condensed consolidated statement of financial position  
As at 31 March 2025

		31 March 2025 SR (Unaudited)	31 December 2024 SR (Audited)
	Notes		
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		2,548,207,994	2,890,702,697
Accounts receivable		1,179,494,212	1,110,377,832
Prepayments and other assets		587,461,501	471,466,187
Inventories		929,027,808	846,880,231
<b>Total current assets</b>		<b>5,244,191,515</b>	<b>5,319,426,947</b>
<b>Non-current assets</b>			
Investments in associates and others		169,210,799	165,353,436
Investment in equity instruments - Sukuk		300,000,000	300,000,000
Property and equipment	7	15,647,289,945	14,773,148,689
<b>Total non-current assets</b>		<b>16,116,500,744</b>	<b>15,238,502,125</b>
<b>Total assets</b>		<b>21,360,692,259</b>	<b>20,557,929,072</b>
<b>Liabilities and equity</b>			
<b>Liabilities</b>			
<b>Current liabilities</b>			
Current portion of long-term loans	11	157,874,831	96,039,119
Accounts payable		2,028,783,026	1,839,938,621
Accruals and other liabilities		2,085,541,373	2,003,645,400
Zakat and income tax payable		81,564,414	147,845,521
Current portion of lease liabilities		77,107,710	74,337,595
<b>Total current liabilities</b>		<b>4,430,871,354</b>	<b>4,161,806,256</b>
<b>Non-current liabilities</b>			
Long-term loans	11	8,001,390,837	7,661,931,031
Government grant		47,694,757	49,039,737
Lease liabilities		350,419,051	333,161,823
Employees' end-of-service benefits		778,565,120	739,342,128
<b>Total non-current liabilities</b>		<b>9,178,069,765</b>	<b>8,783,474,719</b>
<b>Total liabilities</b>		<b>13,608,941,119</b>	<b>12,945,280,975</b>
<b>Equity</b>			
Issued and paid-up share capital		3,500,000,000	3,500,000,000
Retained earnings		3,791,139,193	3,675,142,519
<b>Equity attributable to equity holders of the parent</b>		<b>7,291,139,193</b>	<b>7,175,142,519</b>
Non-controlling interests		460,611,947	437,505,578
<b>Total equity</b>		<b>7,751,751,140</b>	<b>7,612,648,097</b>
<b>Total liabilities and equity</b>		<b>21,360,692,259</b>	<b>20,557,929,072</b>



APPROVED BY:  
FAISAL AL NASSAR  
CFO



APPROVED BY:  
FAISAL AL NASSAR  
CEO



APPROVED BY:  
DR. SULAIMAN AL HABIB  
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Interim condensed consolidated statement of income  
For the three months period ended 31 March 2025

	Notes	For the three months period ended	
		31 March 2025	31 March 2024
		SR	SR
		(Unaudited)	(Unaudited)
Revenue		3,157,779,769	2,521,409,349
Cost of revenue		(2,129,469,373)	(1,644,079,407)
<b>Gross profit</b>		<b>1,028,310,396</b>	<b>877,329,942</b>
Selling and marketing expenses		(132,376,360)	(113,034,796)
General and administrative expenses		(270,005,881)	(208,220,284)
<b>Operating income</b>		<b>625,928,155</b>	<b>556,074,862</b>
Share of income of associates		3,857,363	4,141,692
Finance costs		(78,648,702)	(15,772,735)
Other income		38,573,271	43,188,224
<b>Income before zakat and income tax</b>		<b>589,710,087</b>	<b>587,632,043</b>
Zakat and income tax		(9,927,245)	(15,509,981)
<b>Income for the period</b>		<b>579,782,842</b>	<b>572,122,062</b>
<b>Income for the period attributable to:</b>			
Equity holders of the parent company		557,009,075	550,948,639
Non-controlling interests		22,773,767	21,173,423
		<b>579,782,842</b>	<b>572,122,062</b>
<b>Earnings per share:</b>			
<i>Basic and diluted earnings per share from income for the period attributable to equity holders of the parent company</i>	12	<b>1.59</b>	<b>1.57</b>



APPROVED BY:  
FAISAL AL NASSAR  
CFO



APPROVED BY:  
FAISAL AL NASSAR  
CEO



APPROVED BY:  
DR. SULAIMAN AL HABIB  
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.



Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Interim condensed consolidated statement of comprehensive income  
For the three months period ended 31 March 2025

	For the three months period ended	
	31 March 2025	31 March 2024
	SR	SR
	(Unaudited)	(Unaudited)
Income for the period	579,782,842	572,122,062
Other comprehensive income		
<i>Items that will not to be reclassified to profit or loss in subsequent periods:</i>		
Remeasurement (loss) income on employees' end-of-service benefits	(10,177,035)	470,180
Other comprehensive (loss) income for the period	(10,177,035)	470,180
Total comprehensive income for the period	569,605,807	572,592,242
Total comprehensive income for the period attributable to:		
Equity holders of the parent company	546,496,674	551,896,874
Non-controlling interests	23,109,133	20,695,368
	569,605,807	572,592,242



APPROVED BY:  
FAISAL AL NASSAR  
CFO



APPROVED BY:  
FAISAL AL NASSAR  
CEO



APPROVED BY:  
DR. SULAIMAN AL HABIB  
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Interim condensed consolidated statement of changes in equity  
For the three months period ended 31 March 2025

	Attributable to equity holders of the parent company				Non-controlling interests SR	Total equity SR
	Issued and paid-up share capital SR	Statutory reserve SR	Retained earnings SR	Total SR		
<b>As at 1 January 2025</b>	<b>3,500,000,000</b>	-	<b>3,675,142,519</b>	<b>7,175,142,519</b>	<b>437,505,578</b>	<b>7,612,648,097</b>
Income for the period	-	-	557,009,075	557,009,075	22,773,767	579,782,842
Other comprehensive income (loss)	-	-	(10,512,401)	(10,512,401)	335,366	(10,177,035)
Total comprehensive income	-	-	546,496,674	546,496,674	23,109,133	569,605,807
Dividends (note 10)	-	-	(430,500,000)	(430,500,000)	-	(430,500,000)
Movement in non-controlling interests	-	-	-	-	(2,764)	(2,764)
<b>As at 31 March 2025 (Unaudited)</b>	<b>3,500,000,000</b>	-	<b>3,791,139,193</b>	<b>7,291,139,193</b>	<b>460,611,947</b>	<b>7,751,751,140</b>
<b>As at 1 January 2024</b>	<b>3,500,000,000</b>	<b>1,050,000,000</b>	<b>1,935,484,939</b>	<b>6,485,484,939</b>	<b>280,756,880</b>	<b>6,766,241,819</b>
Income for the period	-	-	550,948,639	550,948,639	21,173,423	572,122,062
Other comprehensive income (loss)	-	-	948,235	948,235	(478,055)	470,180
Total comprehensive income	-	-	551,896,874	551,896,874	20,695,368	572,592,242
Dividends (note 10)	-	-	(402,500,000)	(402,500,000)	-	(402,500,000)
<b>As at 31 March 2024 (Unaudited)</b>	<b>3,500,000,000</b>	<b>1,050,000,000</b>	<b>2,084,881,813</b>	<b>6,634,881,813</b>	<b>301,452,248</b>	<b>6,936,334,061</b>



APPROVED BY:  
FAISAL AL NASSAR  
CFO



APPROVED BY:  
FAISAL AL NASSAR  
CEO



APPROVED BY:  
DR. SULAIMAN AL HABIB  
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Interim condensed consolidated statement of cash flows  
For the three months period ended 31 March 2025

	2025 SR (Unaudited)	2024 SR (Unaudited)
<b>Operating activities</b>		
Income before zakat and income tax	589,710,087	587,632,043
Adjustments for non-cash items:		
Depreciation	151,547,093	81,859,697
Share of income of associates	(3,857,363)	(4,141,692)
Provisions	64,266,636	66,204,154
Finance costs	78,648,702	15,772,735
Employees' end-of-service benefits	36,281,702	35,650,172
	<u>916,596,857</u>	<u>782,977,109</u>
Working capital changes:		
Accounts receivable	(132,916,847)	50,432,350
Inventories	(82,613,746)	(154,429,071)
Prepayments and other assets	(155,673,561)	(86,622,280)
Accounts payable	188,844,405	199,673,835
Accruals and other liabilities	82,798,486	85,078,257
<b>Cash generated from operations</b>	<u>817,035,594</u>	<u>877,110,200</u>
Zakat paid	(76,208,352)	(72,403,704)
Employees' end-of-service benefits paid	(7,235,745)	(8,954,522)
<b>Net cash from operating activities</b>	<u>733,591,497</u>	<u>795,751,974</u>
<b>Investing activities</b>		
Purchase of property and equipment	(934,321,624)	(1,062,373,016)
<b>Net cash used in investing activities</b>	<u>(934,321,624)</u>	<u>(1,062,373,016)</u>
<b>Financing activities</b>		
Proceeds from long-term loans	400,000,000	731,106,475
Repayment of long-term loans	-	(123,671,425)
Lease liabilities paid	(31,661,135)	(14,693,961)
Finance costs paid	(79,600,677)	(14,730,831)
Dividends paid	(430,500,000)	(402,500,000)
Non-controlling interest	(2,764)	-
<b>Net cash (used in) generated from financing activities</b>	<u>(141,764,576)</u>	<u>175,510,258</u>
Net decrease in cash and cash equivalents	(342,494,703)	(91,110,784)
Cash and cash equivalents at the beginning of the period	2,890,702,697	2,620,380,482
<b>Cash and cash equivalents at the end of the period</b>	<u>2,548,207,994</u>	<u>2,529,269,698</u>
<b>Non-cash transactions:</b>		
Recognition of right-of-use assets and lease liabilities	51,688,478	32,731,759



APPROVED BY:  
FAISAL AL NASSAR  
CFO



APPROVED BY:  
FAISAL AL NASSAR  
CEO



APPROVED BY:  
DR. SULAIMAN AL HABIB  
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.



**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries**  
**(Saudi Joint Stock Company)**  
**Notes to the interim condensed consolidated financial statements**  
**31 March 2025**

---

**1. Corporate information and activities**

Dr. Sulaiman Al Habib Medical Services Group Company (the "Company") (a Saudi Joint Stock Company) is registered in Riyadh, under commercial registration number 1010118330 dated 11 Jumada al-thani 1414H (corresponding to 25 November 1993). The registered office is located at Olaya District, P.O. Box 301578, Riyadh 11372, Kingdom of Saudi Arabia (the "Kingdom"), and the Company was listed on the Saudi Stock Exchange (Tadawul) on 22 Rajab 1441H (corresponding to 17 March 2020).

The activities of the Company and its subsidiaries (collectively referred to as "the Group") are to provide private health services and ancillary services for its operations in the Kingdom and the region through the establishment, management, and operation of hospitals, general and specialized medical complexes, day surgery centers, pharmaceutical facilities, and other ancillary areas which include providing services of Home health care, specialized medical laboratories, technology services & information systems, providing facility maintenance services, Tele-medicine services, revenue cycle management services, medical equipment maintenance services, and real estate activity.

The Company has two branches, the first of which is located in Riyadh, Kingdom, under the name "Branch of Dr. Sulaiman Al Habib Medical Services Group Company" ("the Branch"), registered under commercial registration number 1010357146 dated 24 Muharram 1434H (corresponding to 8 December 2012). The Branch is engaged in the activities of retail sales of medical devices, equipment, and supplies, as well as operating pharmaceutical warehouses and general warehouses that store a range of goods. The second branch is located in the Kingdom of Bahrain, "Dr. Sulaiman Al-Habib Medical Services Group Holding Company - Foreign Branch" ("the Foreign Branch") under commercial registration number 81609-1 dated 22 Rajab 1433H (corresponding to 12 June 2012). The Foreign Branch is engaged in activities of head offices and management offices.

The number of shares is 350,000,000 and the share value is 10 Saudi riyals.

The interim condensed consolidated financial statements include the financial information of the branches mentioned above and subsidiaries mentioned in note 3.

**2. Basis of preparation**

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by Saudi Organization for Chartered and Professional Accountants (collectively referred to as International Financial Reporting Standards ("IFRS") as endorsed in Kingdom of Saudi Arabia").

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should therefore be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

An interim condensed consolidated financial statements is considered an integral part of the whole fiscal year, however, the results of operations for the interim periods may not be a fair indication of the results of the full year operations.

These interim condensed consolidated financial statements are prepared on a historical cost basis. The interim condensed consolidated financial statements are presented in Saudi Riyals, which is the functional, and presentation currency of the Company and all values are rounded to the nearest one Riyal, except when otherwise indicated.

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries  
(Saudi Joint Stock Company)  
Notes to the interim condensed consolidated financial statements (continued)  
31 March 2025**

**3. Basis of consolidation**

These interim condensed consolidated financial statements comprise the financial statements of the Company and its following subsidiaries (collectively referred to as "the Group"), mainly domiciled in Kingdom of Saudi Arabia ("KSA") and United Arab Emirates ("UAE") as at 31 March 2025 and 31 December 2024:

	Country of incorporation and business	Activities	Ownership%	
			31 March 2025	31 December 2024
Sehat Al Olaya Medical Complex Company	KSA	Hospital	100%	100%
Asharq Alawsat Pharmacies Company	KSA	Pharmacy	100%	100%
Dr. Sulaiman Al Habib Hospital FZ – LLC	UAE	Hospital	100%	100%
Buraidah Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Rayan Hospital for Healthcare Company	KSA	Hospital	100%	100%
Home Healthcare Company	KSA	Home Healthcare Services	100%	100%
Al Gharb Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Mokhtabarat Diagnostic Medical Company	KSA	Laboratory Services	100%	100%
Sehat Al Suwaidi Medical Company	KSA	Hospital	100%	100%
Hulool Al Sahaba for IT & Communication Company	KSA	IT Services	100%	100%
Rawabet Medical Company	KSA	Medical and Telemedicine Services	100%	100%
Sehat Al Sharq Medical Limited Company	KSA	Hospital	50%	50%
Al Wosta Medical Limited Company	KSA	Hospital	50%	50%
Gharb Jeddah Hospital Company	KSA	Hospital	50%	50%
Shamal Al Riyadh for Healthcare Company	KSA	Hospital	100%	100%
Al Muhammadiyah Hospital for Healthcare Company	KSA	Hospital	100%	100%
Taswyat Administrative Company	KSA	Revenue Cycle Management	100%	100%
Al Marakez Al Awwalyah for Healthcare Company	KSA	Primary Care Centers	100%	100%
Wrass Real Estate Company	KSA	Real Estate	100%	100%
Flow Medical Company	KSA	Medical Equipment Services	100%	100%
Sehat Al Kharj for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Gharb for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Shamal for Healthcare Company	KSA	Hospital	100%	100%
Sehat Al Hamra for Healthcare Company	KSA	Hospital	100%	100%
Wrass for Operation and Maintenance Company	KSA	Ancillary Services	100%	100%
Dr. Sulaiman Al Habib for Education Company	KSA	Higher Education	100%	100%
Bawabat Al Sharq for Healthcare Company	KSA	Hospital	100%	100%

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee;
- The ability to use its power over the investee to affect its returns.

### **3. Basis of consolidation (continued)**

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements;
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognizes the assets and liabilities of the subsidiary;
- Derecognizes the carrying amount of any non-controlling interest;
- Recognizes the fair value of the consideration received;
- Recognizes the fair value of any investment retained;
- Recognizes any surplus or deficit in profit or loss;
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

### **4. Summary of significant accounting policies**

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of new standards effective as of 1 January 2025. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

## 5. New standards effective as of 1 January 2025

### Lack of exchangeability - Amendments to IAS 21

The amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.

The amendments are effective for annual reporting periods beginning on or after 1 January 2025. When applying the amendments, an entity cannot restate comparative information.

The amendments did not have a material impact on the Group's financial statements.

## 6. Segment Information

Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM").

The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group.

The identified key segments are Hospitals / Healthcare Facilities, Pharmacies and HMG Solutions / Others (which includes IT support services, laboratory services, home healthcare services, medical equipments maintenance, revenue cycle management and real estate). The segment results (gross profit) for the period ended 31 March 2025 and the reconciliation of the segment measures to the respective statutory items included in the interim condensed consolidated financial statements are as follows:

<i>SR' millions</i>	<b>Hospitals/ Healthcare Facilities</b>	<b>Pharmacies</b>	<b>HMG Solutions / Others</b>	<b>Total</b>
<b>For the three months period ended 31 March 2025 (Unaudited)</b>				
Revenue	2,433	657	68	3,158
Gross profit	799	192	37	1,028
<b>As at 31 March 2025 (Unaudited)</b>				
Total assets	17,166	737	3,458	21,361
Total liabilities	9,981	876	2,752	13,609
<i>SR' millions</i>	<b>Hospitals/ Healthcare Facilities</b>	<b>Pharmacies</b>	<b>HMG Solutions / Others</b>	<b>Total</b>
<b>For the three months period ended 31 March 2024 (Unaudited)</b>				
Revenue	1,903	544	74	2,521
Gross profit	688	167	22	877
<b>As at 31 December 2024 (audited)</b>				
Total assets	16,131	638	3,789	20,558
Total liabilities	9,797	799	2,349	12,945

## 7. Property and equipment

	<b>As at 31 March 2025 SR (Unaudited)</b>	<b>As at 31 December 2024 SR (Audited)</b>
Property and equipment	15,163,608,114	14,318,897,769
Right-of-use assets	483,681,831	454,250,920
	<b>15,647,289,945</b>	<b>14,773,148,689</b>



## 8. Related party disclosures

Related parties represent shareholders, Directors and key management personnel of the Group, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and the terms of these transactions are approved by the Group's management.

### Related party transactions

Significant transactions and balances with related parties in the ordinary course of business which are included in the interim condensed consolidated financial statements are summarized as follows:

Related party	Nature of transaction	For the three months period ended	
		31 March 2025	31 March 2024
		(Unaudited) SR	(Unaudited) SR
Board of Directors	Purchases and services	460,494	7,585,440
Affiliates Parties	Purchases and services	32,264,131	21,576,421
Associates Parties	Purchases and services	3,586,703	-
Affiliates Parties	Capital work-in-progress	4,497,295	55,631,414
Associates Parties	Revenue	18,978,827	16,071,452

### Compensation of key management personnel of the Group

Key management personnel of the Group comprise of the Board of Directors and key members of management having authority and responsibility for planning, directing and controlling the activities of the Group.

	For the three months period ended	
	31 March 2025	31 March 2024
	(Unaudited) SR	(Unaudited) SR
Short-term employee benefits	3,840,000	3,420,000
Board of Directors and its committees remuneration	745,000	707,250
Post-employment and medical benefits	320,000	285,000
<b>Total compensation paid to key management personnel</b>	<b>4,905,000</b>	<b>4,412,250</b>

## 9. Zakat and Tax

The following table summarizes the zakat status for the Group and its subsidiaries on reporting date:

Zakat Status	Company ownership %	Zakat return filed up to	Zakat Certificate received up to	Final Zakat assessment received up to
Consolidated zakat returns for the Company and its subsidiaries	100	2024	2024	2023
Sehat Al Sharq Medical Limited Company	50	2024	2024	2020
Gharb Jeddah Hospital Company	50	2024	2024	2022
Al Wosta Medical Limited Company	50	2024	2024	2022
Asharq Alawsat Pharmacies Company	100	2024	2024	2023

## 10. Dividends

The Board of Directors, in their meetings on 15 February 2025 resolved to distribute interim dividends of SR 1.23 per share totaling to SR 430,500,000 (2024: SR 1.15 per share totaling to SR 402,500,000.), based on the authorization to distribute interim dividends to the shareholders, quarterly or semi-annually, for the fiscal year 2024 which was granted to the Board of Directors by the Extraordinary General Assembly which was held on Tuesday 6 Dhu al-Qi'dah 1445H (corresponding to 14 May 2024).

## 11. Long-term loans

	As at 31 March 2025 SR (Unaudited)	As at 31 December 2024 SR (Audited)
<b>Current portion of long-term loans:</b>		
Loans from local banks (i)	123,671,425	61,835,713
Loans from Ministry of Finance (ii)	34,203,406	34,203,406
	<b>157,874,831</b>	<b>96,039,119</b>
<b>Non-current portion of long-term loans:</b>		
Loans from local banks (i)	7,713,691,210	7,375,526,921
Loans from Ministry of Finance (ii)	287,699,627	286,404,110
	<b>8,001,390,837</b>	<b>7,661,931,031</b>

- i) Loans from local banks  
The Group is financed through Islamic facilities in the form of long-term and short-term loans (Murabaha / Tawarruq) from local banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin. The facilities are secured by corporate promissory notes.
- ii) Loans from Ministry of Finance (MoF)  
The Group's long-term financing includes MoF non-interest bearing loans to finance the capital expenditures related to the Company and its subsidiaries. The loan repayment instalments are settled on equal yearly installments. Certain assets are pledged against the loans obtained from the MoF.

## **12. Earnings per share**

Basic and diluted earnings per share ("EPS") is calculated by dividing the income for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the income for the period attributable to equity holders of the parent and share data used in the basic and diluted EPS computations:

	<b>For the three months period ended</b>	
	<b>31 March 2025 SR</b>	<b>31 March 2024 SR</b>
Income for the period attributable to equity holders of the parent	<b>557,009,075</b>	<b>550,948,639</b>
Weighted average number of ordinary shares	<b>350,000,000</b>	<b>350,000,000</b>
Basic and diluted earnings per share from income for the period attributable to equity holders of the parent	<b>1.59</b>	<b>1.57</b>

## **13. Fair values**

Financial instruments comprise financial assets and financial liabilities. Financial assets consist of cash and cash equivalents and accounts receivable. Financial liabilities consist of long-term loans, accounts payable, accruals and other liabilities and zakat payable.

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of financial instruments are not materially different from their carrying values at reporting date.

## **14. Subsequent events**

In the opinion of management, no significant events have occurred subsequent to 31 March 2025 that would have a material impact on financial position or financial performance of the Group.

## **15. Approval of the interim condensed consolidated financial statements**

These interim condensed consolidated financial statements were approved for issuance by the Board of Directors on 5 Dhu al-Qi'dah 1446H (corresponding to 3 May 2025).